Petra Nijst1, Frederik H Verbrugge2, Philippe B Bertrand1, Pieter Martens2, Matthias Dupont2, Olivier Drieskens3, Joris Penders4, W H Wilson Tang5, Wilfried Mullens6. 1. Department of Cardiology, Ziekenhuis Oost-Limburg, Genk, Belgium; Doctoral School for Medicine and Life Sciences, Hasselt University, Diepenbeek, Belgium. 2. Department of Cardiology, Ziekenhuis Oost-Limburg, Genk, Belgium. 3. Department of Nuclear Medicine, Ziekenhuis Oost-Limburg, Genk, Belgium. 4. Biomedical Research Institute, Faculty of Medicine and Life Sciences, Hasselt University, Diepenbeek, Belgium. 5. Department of Cardiovascular Medicine, Cleveland Clinic, Heart and Vascular Institute, Cleveland, Ohio. 6. Department of Cardiology, Ziekenhuis Oost-Limburg, Genk, Belgium; Biomedical Research Institute, Faculty of Medicine and Life Sciences, Hasselt University, Diepenbeek, Belgium. Electronic address: wilfried.mullens@zol.be.
Abstract
BACKGROUND: Intravascular volume overload and depletion as well as anemia are associated with increased hospital admissions and mortality in patients with heart failure. This study aimed to accurately measure plasma volume and red cell mass (RCM) in stable patients with chronic heart failure with reduced ejection fraction (HFrEF) and gain more insight into plasma volume regulation and anemia in stable conditions of HFrEF. METHODS AND RESULTS: Plasma volume and RCM measurement based on 99Tc-labeled red blood cells, venous blood sample,s and clinical parameters were obtained in 24 stable HFrEF patients under optimal medical therapy. Measured plasma volume values were compared with predicted values based on body surface area. Plasma volume was on average normal (99.98% of predicted) but heterogeneously distributed (variations of 81%-133%). Neurohumoral activation and medication use were not associated with plasma volume status. Furthermore, anemia based on actual measurement of RCM was present in up to 75% of subjects, but rarely hemodilutional. CONCLUSIONS: In stable chronic HFrEF patients under optimal medical therapy, plasma volume is overall normal but heterogeneously distributed. Anticipated factors such as neurohumoral activation and heart failure medication were not associated with plasma volume. Furthermore, anemia is more common than as assessed by hemoglobin.
BACKGROUND: Intravascular volume overload and depletion as well as anemia are associated with increased hospital admissions and mortality in patients with heart failure. This study aimed to accurately measure plasma volume and red cell mass (RCM) in stable patients with chronic heart failure with reduced ejection fraction (HFrEF) and gain more insight into plasma volume regulation and anemia in stable conditions of HFrEF. METHODS AND RESULTS: Plasma volume and RCM measurement based on 99Tc-labeled red blood cells, venous blood sample,s and clinical parameters were obtained in 24 stable HFrEF patients under optimal medical therapy. Measured plasma volume values were compared with predicted values based on body surface area. Plasma volume was on average normal (99.98% of predicted) but heterogeneously distributed (variations of 81%-133%). Neurohumoral activation and medication use were not associated with plasma volume status. Furthermore, anemia based on actual measurement of RCM was present in up to 75% of subjects, but rarely hemodilutional. CONCLUSIONS: In stable chronic HFrEF patients under optimal medical therapy, plasma volume is overall normal but heterogeneously distributed. Anticipated factors such as neurohumoral activation and heart failure medication were not associated with plasma volume. Furthermore, anemia is more common than as assessed by hemoglobin.
Authors: Marat Fudim; Christopher M O'Connor; Hillary Mulder; Adrian Coles; Ankeet S Bhatt; Andrew P Ambrosy; William E Kraus; Ileana L Piña; David J Whellan; Robert J Mentz Journal: Am Heart J Date: 2018-07-29 Impact factor: 4.749
Authors: Kenneth C Bilchick; Nathaniel Chishinga; Alex M Parker; David X Zhuo; Mitchell H Rosner; LaVone A Smith; Hunter Mwansa; Jacob N Blackwell; Peter A McCullough; Sula Mazimba Journal: Cardiorenal Med Date: 2017-11-03 Impact factor: 2.041